Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ami Mankodi is active.

Publication


Featured researches published by Ami Mankodi.


Annals of clinical and translational neurology | 2014

Lysosomal abnormalities in hereditary spastic paraplegia types SPG15 and SPG11

Benoı̂t Renvoisé; Jaerak Chang; Rajat Singh; Sayuri Yonekawa; Edmond J. FitzGibbon; Ami Mankodi; Adeline Vanderver; Alice B. Schindler; Camilo Toro; William A. Gahl; Don J. Mahuran; Craig Blackstone; Tyler Mark Pierson

Hereditary spastic paraplegias (HSPs) are among the most genetically diverse inherited neurological disorders, with over 70 disease loci identified (SPG1‐71) to date. SPG15 and SPG11 are clinically similar, autosomal recessive disorders characterized by progressive spastic paraplegia along with thin corpus callosum, white matter abnormalities, cognitive impairment, and ophthalmologic abnormalities. Furthermore, both have been linked to early‐onset parkinsonism.


Journal of Biological Chemistry | 2014

Z-disc-associated, Alternatively Spliced, PDZ Motif-containing Protein (ZASP) Mutations in the Actin-binding Domain Cause Disruption of Skeletal Muscle Actin Filaments in Myofibrillar Myopathy

Xiaoyan Lin; Janelle Ruiz; Ilda Bajraktari; Rachel Ohman; Soojay Banerjee; Katherine Gribble; Joshua D. Kaufman; Paul T. Wingfield; Robert C. Griggs; Kenneth H. Fischbeck; Ami Mankodi

Background: The binding partners of the ZASP internal region that is mutated in zaspopathy are not yet known. Results: The internal region of ZASP binds to skeletal muscle α-actin, and zaspopathy mutations cause actin disruption. Conclusion: ZASP mutations in the actin-binding domain are deleterious to the muscle Z-disc structure. Significance: ZASP-actin interaction expands the role of ZASP and defines the mechanism of zaspopathy. The core of skeletal muscle Z-discs consists of actin filaments from adjacent sarcomeres that are cross-linked by α-actinin homodimers. Z-disc-associated, alternatively spliced, PDZ motif-containing protein (ZASP)/Cypher interacts with α-actinin, myotilin, and other Z-disc proteins via the PDZ domain. However, these interactions are not sufficient to maintain the Z-disc structure. We show that ZASP directly interacts with skeletal actin filaments. The actin-binding domain is between the modular PDZ and LIM domains. This ZASP region is alternatively spliced so that each isoform has unique actin-binding domains. All ZASP isoforms contain the exon 6-encoded ZASP-like motif that is mutated in zaspopathy, a myofibrillar myopathy (MFM), whereas the exon 8–11 junction-encoded peptide is exclusive to the postnatal long ZASP isoform (ZASP-LΔex10). MFM is characterized by disruption of skeletal muscle Z-discs and accumulation of myofibrillar degradation products. Wild-type and mutant ZASP interact with α-actin, α-actinin, and myotilin. Expression of mutant, but not wild-type, ZASP leads to Z-disc disruption and F-actin accumulation in mouse skeletal muscle, as in MFM. Mutations in the actin-binding domain of ZASP-LΔex10, but not other isoforms, cause disruption of the actin cytoskeleton in muscle cells. These isoform-specific mutation effects highlight the essential role of the ZASP-LΔex10 isoform in F-actin organization. Our results show that MFM-associated ZASP mutations in the actin-binding domain have deleterious effects on the core structure of the Z-discs in skeletal muscle.


American Journal of Human Genetics | 2013

A Dominant Mutation in FBXO38 Causes Distal Spinal Muscular Atrophy with Calf Predominance

Charlotte J. Sumner; Constantin D'Ydewalle; Joe Wooley; Katherine Fawcett; Dena Hernandez; A Gardiner; Bernadett Kalmar; Robert H. Baloh; Michael Gonzalez; Stephan Züchner; Horia Stanescu; Robert Kleta; Ami Mankodi; David R. Cornblath; Kevin B. Boylan; Mary M. Reilly; Linda Greensmith; Andrew Singleton; Matthew B. Harms; Alexander M. Rossor; Henry Houlden

Spinal muscular atrophies (SMAs) are a heterogeneous group of inherited disorders characterized by degeneration of anterior horn cells and progressive muscle weakness. In two unrelated families affected by a distinct form of autosomal-dominant distal SMA initially manifesting with calf weakness, we identified by genetic linkage analysis and exome sequencing a heterozygous missense mutation, c.616T>C (p.Cys206Arg), in F-box protein 38 (FBXO38). FBXO38 is a known coactivator of the transcription factor Krüppel-like factor 7 (KLF7), which regulates genes required for neuronal axon outgrowth and repair. The p.Cys206Arg substitution did not alter the subcellular localization of FBXO38 but did impair KLF7-mediated transactivation of a KLF7-responsive promoter construct and endogenous KLF7 target genes in both heterologously expressing human embryonic kidney 293T cells and fibroblasts derived from individuals with the FBXO38 missense mutation. This transcriptional dysregulation was associated with an impairment of neurite outgrowth in primaryxa0motor neurons. Together, these results suggest that a transcriptional regulatory pathway that has a well-established role inxa0axonal development could also be critical for neuronal maintenance and highlight the importance of FBXO38 and KLF7 activity in motor neurons.


Neuromuscular Disorders | 2015

Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies

Katherine G. Meilleur; M. Jain; Linda S. Hynan; C.Y. Shieh; Eunice Kim; M. Waite; M. McGuire; Courtney Fiorini; Allan M. Glanzman; M. Main; Kristy J. Rose; T. Duong; Roxanna Bendixen; Melody M. Linton; I. Arveson; Carmel Nichols; K. Yang; Kenneth H. Fischbeck; Kathryn R. Wagner; Kathryn N. North; Ami Mankodi; Christopher Grunseich; Elizabeth J. Hartnett; Michaele Smith; Sandra Donkervoort; Alice B. Schindler; Angela Kokkinis; Meganne Leach; A. Reghan Foley; James J. Collins

Potential therapies are currently under development for two congenital muscular dystrophy (CMD) subtypes: collagen VI-related muscular dystrophy (COL6-RD) and laminin alpha 2-related dystrophy (LAMA2-RD). However, appropriate clinical outcome measures to be used in clinical trials have not been validated in CMDs. We conducted a two-year pilot study to evaluate feasibility, reliability, and validity of various outcome measures, particularly the Motor Function Measure 32, in 33 subjects with COL6-RD and LAMA2-RD. In the first year, outcome measures tested included: Motor Function Measure 32 (MFM32), forced vital capacity (FVC) percent predicted sitting, myometry, goniometry, 10-meter walk, Egen Klassification 2, and PedsQL(TM) Generic and Neuromuscular Cores. In the second year, we added the North Star Ambulatory Assessment (NSAA), Hammersmith Functional Motor Scale (HFMS), timed functional tests, Measure of Activity Limitations (ACTIVLIM), Quality of Upper Extremity Skills Test (QUEST), and Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue subscale. The MFM32 showed strong inter-rater (0.92) and internal consistency (0.96) reliabilities. Concurrent validity for the MFM32 was supported by large correlations (range 0.623-0.936) with the following: FVC, NSAA, HFMS, timed functional tests, ACTIVLIM, and QUEST. Significant correlations of the MFM32 were also found with select myometry measurements, mainly of the proximal extremities and domains of the PedsQL(TM) scales focusing on physical health and neuromuscular disease. Goniometry measurements were less reliable. The Motor Function Measure is reliable and valid in the two specific subtypes of CMD evaluated, COL6-RD and LAMA2-RD. The NSAA is useful as a complementary outcome measure in ambulatory individuals. Preliminary concurrent validity of several other clinical outcome measures was also demonstrated for these subtypes.


Neuromuscular Disorders | 2016

Quantifying disease activity in fatty-infiltrated skeletal muscle by IDEAL-CPMG in Duchenne muscular dystrophy

Ami Mankodi; Courtney A. Bishop; Sungyoung Auh; Rexford D. Newbould; Kenneth H. Fischbeck; Robert L. Janiczek

The purpose of this study was to explore the use of iterative decomposition of water and fat with echo asymmetry and least-squares estimation Carr-Purcell-Meiboom-Gill (IDEAL-CPMG) to simultaneously measure skeletal muscle apparent fat fraction and water T2 (T2,w) in patients with Duchenne muscular dystrophy (DMD). In twenty healthy volunteer boys and thirteen subjects with DMD, thigh muscle apparent fat fraction was measured by Dixon and IDEAL-CPMG, with the IDEAL-CPMG also providing T2,w as a measure of muscle inflammatory activity. A subset of subjects with DMD was followed up during a 48-week clinical study. The study was in compliance with the Patient Privacy Act and approved by the Institutional Review Board. Apparent fat fraction in the thigh muscles of subjects with DMD was significantly increased compared to healthy volunteer boys (pu2009<0.001). There was a strong correlation between Dixon and IDEAL-CPMG apparent fat fraction. Muscle T2,w measured by IDEAL-CPMG was independent of changes in apparent fat fraction. Muscle T2,w was higher in the biceps femoris and vastus lateralis muscles of subjects with DMD (pu2009<0.05). There was a strong correlation (pu2009<0.004) between apparent fat fraction in all thigh muscles and six-minute walk distance (6MWD) in subjects with DMD. IDEAL-CPMG allowed independent and simultaneous quantification of skeletal muscle fatty degeneration and disease activity in DMD. IDEAL-CPMG apparent fat fraction and T2,w may be useful as biomarkers in clinical trials of DMD as the technique disentangles two competing biological processes.


Neuromuscular Disorders | 2014

Atypical presentation of GNE myopathy with asymmetric hand weakness

John Karl de Dios; Joseph A. Shrader; Galen O. Joe; Jeffrey C. McClean; Kayla Williams; Robert Evers; May Christine V. Malicdan; Carla Ciccone; Ami Mankodi; Marjan Huizing; John C. McKew; David A. Bluemke; William A. Gahl; Nuria Carrillo-Carrasco

GNE myopathy is a rare autosomal recessive muscle disease caused by mutations in GNE, the gene encoding the rate-limiting enzyme in sialic acid biosynthesis. GNE myopathy usually manifests in early adulthood with distal myopathy that progresses slowly and symmetrically, first involving distal muscles of the lower extremities, followed by proximal muscles with relative sparing of the quadriceps. Upper extremities are typically affected later in the disease. We report a patient with GNE myopathy who presented with asymmetric hand weakness. He had considerably decreased left grip strength, atrophy of the left anterior forearm and fibro-fatty tissue replacement of left forearm flexor muscles on T1-weighted magnetic resonance imaging. The patient was an endoscopist and thus the asymmetric hand involvement may be associated with left hand overuse in daily repetitive pinching and gripping movements, highlighting the possible impact of environmental factors on the progression of genetic muscle conditions.


Annals of clinical and translational neurology | 2016

Upper arm and cardiac magnetic resonance imaging in Duchenne muscular dystrophy

Lasya Gaur; Alexander Hanna; W. Patricia Bandettini; Kenneth H. Fischbeck; Andrew E. Arai; Ami Mankodi

We analyzed quantitative maps of T1 and T2 relaxation times and muscle fat fraction measurements in magnetic resonance imaging of the upper arm skeletal muscles and heart in ambulatory boys with Duchenne muscular dystrophy and age‐range‐matched healthy volunteer boys. The cardiac‐optimized sequences detected fatty infiltration and edema in the upper arm skeletal muscles but not the myocardium in these Duchenne muscular dystrophy boys who had normal ejection fraction. Imaging the heart and skeletal muscle using the same magnetic resonance imaging methods during a single scan may be useful in assessing relative disease status and therapeutic response in clinical trials of Duchenne muscular dystrophy.


Frontiers in Neurology | 2018

Novel Variants in Individuals with RYR1-Related Congenital Myopathies: Genetic, Laboratory, and Clinical Findings

Joshua J. Todd; Muslima S. Razaqyar; J. Witherspoon; Tokunbor A. Lawal; Ami Mankodi; Irene C. Chrismer; Carolyn Allen; Mary D. Meyer; Anna Kuo; Monique S. Shelton; Kim Amburgey; Dmitriy Niyazov; Pierre Fequiere; Carsten G. Bönnemann; James J. Dowling; Katherine G. Meilleur

The ryanodine receptor 1-related congenital myopathies (RYR1-RM) comprise a spectrum of slow, rare neuromuscular diseases. Affected individuals present with a mild-to-severe symptomatology ranging from proximal muscle weakness, hypotonia and joint contractures to scoliosis, ophthalmoplegia, and respiratory involvement. Although there is currently no FDA-approved treatment for RYR1-RM, our group recently conducted the first clinical trial in this patient population (NCT02362425). This study aimed to characterize novel RYR1 variants with regard to genetic, laboratory, muscle magnetic resonance imaging (MRI), and clinical findings. Genetic and histopathology reports were obtained from participant’s medical records. Alamut Visual Software was used to determine if participant’s variants had been previously reported and to assess predicted pathogenicity. Physical exams, pulmonary function tests, T1-weighted muscle MRI scans, and blood measures were completed during the abovementioned clinical trial. Six novel variants (two de novo, three dominant, and one recessive) were identified in individuals with RYR1-RM. Consistent with established RYR1-RM histopathology, cores were observed in all biopsies, except Case 6 who exhibited fiber-type disproportion. Muscle atrophy and impaired mobility with Trendelenburg gait were the most common clinical symptoms and were identified in all cases. Muscle MRI revealed substantial inter-individual variation in fatty infiltration corroborating the heterogeneity of the disease. Two individuals with dominant RYR1 variants exhibited respiratory insufficiency: a clinical symptom more commonly associated with recessive RYR1-RM cases. This study demonstrates that a genetics-led approach is suitable for the diagnosis of suspected RYR1-RM which can be corroborated through histopathology, muscle MRI and clinical examination.


Biochemistry | 2017

Expression and Purification of ZASP Subdomains and Clinically Important Isoforms: High-Affinity Binding to G-Actin

Norman R. Watts; Xiaolei Zhuang; Joshua D. Kaufman; Ira Palmer; Altaira D. Dearborn; Stephen Coscia; Yotam Blech-Hermoni; Caterina Alfano; Annalisa Pastore; Ami Mankodi; Paul T. Wingfield

Z-disc-associated, alternatively spliced, PDZ motif-containing protein (ZASP) is a principal component of the sarcomere. The three prevalent isoforms of ZASP in skeletal muscle are generated by alternative splicing of exons 9 and 10. The long isoforms, either having (ZASP-L) or lacking exon 10 (ZASP-LΔex10), include an N-terminal PDZ domain, an actin-binding region (ABR) with a conserved motif (ZM), and three C-terminal LIM domains. The short isoform (ZASP-S) lacks the LIM domains. Mutations, A147T and A165V, within the ZM of ZASP-LΔex10 cause myofibrillar myopathy, but the mechanism is unknown. We have prepared these proteins, their ABR, and the respective mutant variants in recombinant form, characterized them biophysically, and analyzed their actin-binding properties by surface plasmon resonance and electron microscopy. All the proteins were physically homogeneous and monomeric and had circular dichroic spectra consistent with partially folded conformations. Comparison of the NMR HSQC spectra of ZASP-S and the PDZ domain showed that the ABR is unstructured. ZASP-S and its mutant variants and ZASP-LΔex10 all bound to immobilized G-actin with high affinity (Kd ≈ 10-8 to 10-9 M). Constructs of the isolated actin-binding region missing exon 10 (ABRΔ10) bound with lower affinity (Kd ≈ 10-7 M), but those retaining exon 10 (ABR+10) did so only weakly (Kd ≈ 10-5 M). ZASP-S, and the ABRΔ10, also induced F-actin and array formation, even in conditions of low ionic strength and in the absence of KCl and Mg2+ ions. Interestingly, the ZM mutations A147T and A165V did not affect any of the results described above.


Annals of clinical and translational neurology | 2017

Respiratory magnetic resonance imaging biomarkers in Duchenne muscular dystrophy

Ami Mankodi; William Kovacs; Gina Norato; Nathan Hsieh; W. Patricia Bandettini; Courtney A. Bishop; Hirity Shimellis; Rexford D. Newbould; Eunhee Kim; Kenneth H. Fischbeck; Andrew E. Arai; Jianhua Yao

To examine the diaphragm and chest wall dynamics with cine breathing magnetic resonance imaging (MRI) in ambulatory boys with Duchenne muscular dystrophy (DMD) without respiratory symptoms and controls.

Collaboration


Dive into the Ami Mankodi's collaboration.

Top Co-Authors

Avatar

Kenneth H. Fischbeck

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Alice B. Schindler

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Andrew E. Arai

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Carsten G. Bönnemann

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Christopher Grunseich

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Sandra Donkervoort

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ilda Bajraktari

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Jianhua Yao

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

M. Jain

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge